



# Infasurf® (calfactant) closely resembles native lung surfactant in both composition and activity

Made in the U.S.A. and obtained directly from newborn calf lung lining liquid.

## Native Lung Surfactant<sup>1</sup>



## Infasurf® (calfactant)<sup>2</sup>




Infasurf® (calfactant) is native lung surfactant without SP-A.

- Approved for prevention and treatment of Respiratory Distress Syndrome (RDS)<sup>3</sup>
- Rapid onset of action<sup>4</sup>
- Sustained respiratory improvement<sup>4,5</sup>
- Demonstrates single-dose success<sup>6,7,8</sup>
- Lowest viscosity<sup>9,10</sup>
- Highly potent<sup>9,11</sup>
- Only surfactant available in the U.S. containing a natural cholesterol level<sup>12</sup>
- Cost effective<sup>7</sup>

There are no prospective, randomized clinical trials comparing Infasurf® and Curosurf® with respect to safety or efficacy.

## Approximate Dynamic Viscosities of Common Substances<sup>13,14</sup>



Please see Important Safety Information.

\*At room temperature.

## INDICATION

Infasurf is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment of premature infants who develop RDS. Infasurf decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS.

## Prophylaxis

Prophylaxis therapy at birth with Infasurf is indicated for premature infants <29 weeks of gestational age at significant risk for RDS. Infasurf prophylaxis should be administered as soon as possible, preferably within 30 minutes after birth.

## Treatment

Infasurf therapy is indicated for infants ≤72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.

## IMPORTANT SAFETY INFORMATION

Infasurf is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING INFASURF, OFTEN RAPIDLY IMPROVES OXYGENATION AND LUNG COMPLIANCE. Following administration of Infasurf, patients should be carefully monitored so that oxygen therapy and ventilatory support can be modified in response to changes in respiratory status.

Infasurf therapy is not a substitute for neonatal intensive care. Optimal care of premature infants at risk for RDS and newborn infants with RDS who need endotracheal intubation requires an acute care unit organized, staffed, equipped,

and experienced with intubation, ventilator management, and general care of these patients.

TRANSIENT EPISODES OF REFLUX OF INFASURF INTO THE ENDOTRACHEAL TUBE, CYANOSIS, BRADYCARDIA, OR AIRWAY OBSTRUCTION HAVE OCCURRED DURING THE DOSING PROCEDURES that required stopping Infasurf and taking appropriate measures to alleviate the condition. After the patient is stable, dosing can proceed with appropriate monitoring.

An increased proportion of patients with both intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) was observed in Infasurf-treated infants in the Infasurf-Exosurf Neonatal controlled trials. These observations were not associated with increased mortality.

The most common adverse reactions associated with Infasurf dosing procedures in the controlled trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%). These events were generally transient and not associated with serious complications or death.

The incidence of common complications of prematurity and RDS in the four controlled Infasurf trials are presented in the Table. Prophylaxis and treatment study results for each surfactant are combined.

**Please see accompanying full prescribing information and refer to list of Re-Dose Rate Publications included in pocket.**

Common Complications of Prematurity and RDS in Controlled Trials	Infasurf <sup>®</sup> (n=1001), %	Exosurf Neonatal <sup>®</sup> (n=978), %	Infasurf <sup>®</sup> (n=553), %	Survanta <sup>®</sup> (n=566), %
Apnea	61	61	76	76
Patent ductus arteriosus	47	48	45	48
Intracranial hemorrhage	29	31	36	36
Severe intracranial hemorrhage <sup>a</sup>	12	10	9	7
IVH and PVL <sup>b</sup>	7	3	5	5
Sepsis	20	22	28	27
Pulmonary air leaks	12	22	15	15
Pulmonary interstitial emphysema	7	17	10	10
Pulmonary hemorrhage	7	7	7	6
Necrotizing enterocolitis	5	5	17	18

<sup>a</sup> Grade III and IV by the method of Papile.  
<sup>b</sup> Patients with both intraventricular hemorrhage and periventricular leukomalacia.

**To receive additional information about product specifics, cost benefits and education, please contact:**

## References:

1. Notter RH. Lung Surfactants. Michael Dekker, New York, 2000, pp 171-232; 319-345.
2. Data on file, ONY Biotech.
3. Infasurf<sup>®</sup> (calfactant) Intratracheal Suspension Prescribing Information, ONY Biotech, March 2018.
4. Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of Respiratory Distress Syndrome. *Pediatrics*. 1997;100:31-38.
5. Attar M, Becker M, Dechert R, et al. Immediate changes in lung compliance following natural surfactant administration in premature infants with Respiratory Distress Syndrome: a controlled trial. *J Perinatol*. 2004;24:626-630.
6. Jeon GW, Oh M, Sin JB. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with Respiratory Distress Syndrome: A retrospective study. *Yonsei Med J*. 2015;56(2):433-439.
7. Zayek MM, Eyal FG, Smith RC. Comparison of the pharmacoeconomics of calfactant and poractant alfa in surfactant replacement therapy. *JPPT*. 2018;23(2):146-151.
8. Gerdes JS, Seiberlich W, Sivieri EM, et al. An open label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources. *J Pediatr Pharmacol Ther*. 2006;11(2):92-100.
9. Wang Z, Notter RH. Additivity of protein and nonprotein inhibitors of lung surfactant activity. *Am J Respir Crit Care Med*. 1998;158:28-35.
10. Swartz D, Klein W, Row S, et al. Comparison of dynamic viscosities of lung surfactant drugs. Poster presented Hot Topics. 2017.
11. Seeger W, Gruba C, Gunther A, et al. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. *Eur Respir J*. 1993;6:971-977.
12. Kim K, Choi S, Zell Z, et al. Effect of cholesterol nanodomains on monolayer morphology and dynamics. *Proc Natl Acad Sci USA*. 2013;110:E3054-60.
13. Retrieved from <https://epakmachinery.com/viscosity-chart-1/>
14. Retrieved from [https://en.wikipedia.org/wiki/Saline\\_water](https://en.wikipedia.org/wiki/Saline_water).

ONY Biotech is a leader in the creation of critically important products for the treatment of premature infants.

Since 1998, ONY Biotech has made tomorrow possible for so many premature babies and their families, thanks to Infasurf<sup>®</sup> (calfactant).



**Infasurf<sup>®</sup>**  
(calfactant)

Manufactured by ONY Biotech

1576 Sweet Home Road | Amherst, NY 14228 | 716.636.9096 | 877.274.4669

[infasurf.com](http://infasurf.com)



Please see additional information in pocket.

Infasurf<sup>®</sup> is a registered trademark of ONY Biotech Inc.  
 CUROSURF<sup>®</sup> is a registered trademark of Chiesi Farmaceutici S.p.A.  
 Survanta<sup>®</sup> is a registered trademark of Abbott Laboratories, Inc.  
 ©2020 ONY Biotech Inc. All rights reserved. APM-0093B 7/2020